Taysha Gene Therapies, Inc. (TSHA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Taysha Gene Therapies, Inc. (TSHA) closed at USD 3.51 on 2026-10-14, a change of -29.7 % over the past year, with a market capitalization of USD 1.22B.

Taysha Gene Therapies, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Taysha Gene Therapies, Inc. key figures

Previous close

USD 3.51 (2026-10-14)

1-year change

-29.7 %

Market cap

USD 1.22B

Enterprise value

USD 816.67M

P/E ratio (trailing)

-9.33

P/E ratio (forward)

-8.07

EPS (trailing)

-0.40

EPS (forward)

-0.46

PEG ratio

n/a

Price to book

3.13

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

14.29

Employees

99

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Taysha Gene Therapies, Inc.

Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Taysha Gene Therapies, Inc. and compare it with other stocks.